Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strata Critical MedicalSRTA -1.55%68 5-Year Yield-on-Cost % is 0.00 as of Jul. 22, 2026. GuruFocus rates SRTA with a GF Score™ of 68/100 and a GF Value™ of $4.48 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 277 Healthcare Providers & Services companies, Strata Critical Medical ranks worse than 361010.47% on this metric.
The historical rank and industry rank for Strata Critical Medical's 5-Year Yield-on-Cost % or its related term are showing as below:
SRTA's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.93 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Strata Critical Medical (NAS:SRTA) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Strata Critical Medical 5-Year Yield-on-Cost % Related Terms
SRTA vs CYH, CCRN, AUNA: 5-Year Yield-on-Cost % Comparison
For the Medical Care Facilities subindustry, Strata Critical Medical's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Critical Medical 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Strata Critical Medical's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Strata Critical Medical's 5-Year Yield-on-Cost % falls into.
Strata Critical Medical 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Strata Critical Medical (SRTA) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 22, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Strata Critical Medical and its competitors. According to the industry distribution chart, Strata Critical Medical ranks #999999 out of 277 companies in the Healthcare Providers & Services industry.
Is Strata Critical Medical's 5-Year Yield-on-Cost % too high?
Strata Critical Medical's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Strata Critical Medical ranks #999999 out of 277 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Strata Critical Medical has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strata Critical Medical's 5-Year Yield-on-Cost % compare to CYH and CCRN?
According to the Healthcare Providers & Services industry distribution chart, Strata Critical Medical ranks #999999 out of 277 companies for 5-Year Yield-on-Cost %. This places Strata Critical Medical in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.93, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Strata Critical Medical and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Critical Medical's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Critical Medical stock overvalued right now?
Based on GuruFocus' analysis, Strata Critical Medical (SRTA) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.48, compared to a current price of $5.08 — trading 13.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Strata Critical Medical's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Strata Critical Medical (SRTA), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Critical Medical (SRTA) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Critical Medical stock appears to be overvalued.
The current stock price of $5.08 is trading 13.4% above its estimated GF Value™ of $4.48.
GuruFocus considers Strata Critical Medical to be Modestly Overvalued.
Key valuation signals for SRTA:
5-Year Yield-on-Cost %: 0.00
GF Value™: $4.48 vs. price of $5.08 (13.4% above fair value)
No single metric tells the full story. See the SRTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
68GF Score
Get the complete analysis for SRTA
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTA has been successfully added to your 
